PRKN and Parkinson disease: The remaining 18 patients negative for the LRRK2 G2019S mutation were subjected to high-resolution CMA using an Affymterix platform and CytoscanHD microarrays, which revealed microdeletion chromosomal region 6q26 of the PRKN in 3 of the 18 consanguineous PD patients (16.7%).